On the basis of the described findings, we hypothesized that those patients with a low DA activity genetic profile (low density or affinity for DRD2 and DRD4, higher DAT reuptake, and higher DA catabolism through COMT, which would contribute to a lower availability of DA) may have higher risk of obesity and adverse cardiometabolic effects when treated with SGAs. Here, SLC6A3 is linked to obesity disorder.